Vikas Sinha
CIK 1337845 · Chief Financial Officer · last filed 2026-04-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
352 KNOTTER DRIVE
CHESHIRE, CT 06410
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SRRK | Chief Financial Officer | 619,856 | $51.18 | $31.72M | -$1.23M | 5 | 2026-04-20 |
| Verona Pharma plc (VRNA) Delisted | Director | 0 | $106.91 | $0 | -$3.18M | 12 | 2025-10-08 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | See Remarks | 774,118 | $9.81 | $7.59M | -$246.5K | 40 | 2025-02-24 |
Recent Filings · Page 5 of 17
162 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-03 | KLRS | Notice (144) | −4,957 | -$3.9K | EDGAR |
| 2024-04-30 | Verona Pharma plc (VRNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-23 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −3,378 | -$2.5K | EDGAR |
| 2024-04-22 | KLRS | Notice (144) | −1,857 | -$1.4K | EDGAR |
| 2024-04-19 | KLRS | Notice (144) | −1,521 | -$1.1K | EDGAR |
| 2024-04-04 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −885 | -$683 | EDGAR |
| 2024-04-02 | KLRS | Notice (144) | −885 | -$683 | EDGAR |
| 2024-02-22 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −2,893 | -$2.0K | EDGAR |
| 2024-02-20 | KLRS | Notice (144) | −2,893 | -$2.0K | EDGAR |
| 2024-02-06 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −18,331 | -$12.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.